Cole H Sterling, Michael S Hughes, Hua-Ling Tsai, Kathryn Yarkony, Ephraim J Fuchs, Lode J Swinnen, Suman Paul, Javier Bolaños-Meade, Leo Luznik, Philip H Imus, Syed Abbas Ali, Tania Jain, Alexander Ambinder, Amy DeZern, Carol Ann Huff, Christian B Gocke, Ravi Varadhan, Nina Wagner-Johnston, Richard J Jones, Richard F Ambinder
BACKGROUND: The use of post-transplantation cyclophosphamide (PTCy) for graft-versus host-disease (GVHD) prophylaxis has revolutionized allogeneic blood or marrow transplantation (alloBMT), but there is limited published experience in peripheral T-cell lymphoma (PTCL). OBJECTIVES: We sought to assess outcomes in patients with PTCL who underwent alloBMT with PTCy. STUDY DESIGN: We reviewed the charts of all adult patients aged 18 years or older who underwent alloBMT with non-myeloablative conditioning and PTCy-based GVHD prophylaxis at the Sidney Kimmel Comprehensive Cancer Center between January 2004 and December 2020...
December 19, 2022: Transplantation and cellular therapy